Daily Stock Analysis, HOLX, Hologic Inc, priceseries

Hologic Inc. Daily Stock Analysis
Stock Information
Open
72.41
Close
71.65
High
72.69
Low
70.89
Previous Close
72.22
Daily Price Gain
-0.57
YTD High
76.51
YTD High Date
Jan 3, 2022
YTD Low
67.49
YTD Low Date
Jan 28, 2022
YTD Price Change
-1.45
YTD Gain
-1.98%
52 Week High
81.04
52 Week High Date
Sep 10, 2021
52 Week Low
60.10
52 Week Low Date
Jun 8, 2021
52 Week Price Change
0.74
52 Week Gain
1.04%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Jan 7. 2019
40.49
Jan 31. 2019
43.47
17 Trading Days
7.36%
Link
LONG
Jun 4. 2019
45.08
Jun 26. 2019
47.91
16 Trading Days
6.28%
Link
LONG
Apr 6. 2020
35.86
May 14. 2020
50.09
27 Trading Days
39.68%
Link
LONG
Jul 14. 2020
59.43
Aug 7. 2020
68.78
18 Trading Days
15.73%
Link
LONG
Sep 25. 2020
64.35
Oct 13. 2020
67.68
12 Trading Days
5.17%
Link
LONG
Jun 21. 2021
63.17
Jul 14. 2021
67.81
16 Trading Days
7.34%
Link
Company Information
Stock Symbol
HOLX
Exchange
NasdaqGS
Company URL
http://www.hologic.com
Company Phone
5082632900
CEO
Stephen P. MacMillan
Headquarters
Massachusetts
Business Address
250 CAMPUS DRIVE, MARLBOROUGH, MA 01752
Sector
Equity
Industry Category
Health Services
Industry Group
Medical Appliances & Equipment
CIK
0000859737
About

Hologic, Inc. engages in the development, manufacture and supply diagnostics products, medical imaging systems and surgical products dedicated to serve the healthcare needs of women. The company operates through four business segments: Breast Health, Diagnostics, GYN Surgical and Skeletal Health. The Breast Health segment products include a broad portfolio of breast imaging and related products and accessories, including digital and film-based mammography systems, magnetic resonance imaging, breast coils, computer-aided detection for mammography and MRI, minimally invasive breast biopsy devices, breast biopsy site markers, breast biopsy guidance systems, breast imaging comfort pads, and breast brachytherapy products. It has also developed a new breast imaging platform, Dimensions, which utilizes a new technology, tomosynthesis, to produce three dimensional images, as well as conventional two dimensional full field digital mammography images. The Diagnostics segment products include the ThinPrep system, which is primarily used in cytology applications such as cervical cancer screening, the Rapid Fetal Fibronectin Test, which assists physicians in assessing the risk of pre-term birth, and its molecular diagnostic reagents used for a variety of DNA and RNA analysis applications based on its proprietary Invader chemistry. Its current molecular diagnostic offerings based upon this Invader chemistry include Cervista HPV high risk and Cervista HPV 16/18 products to assist in the diagnosis of human papillomavirus, as well as other products to diagnose cystic fibrosis, cardiovascular risk and other diseases. The GYN Surgical segment products include the NovaSure Endometrial Ablation System and the MyoSure Hysteroscopic Tissue Removal System. The MyoSure system is a tissue removal device that is designed to provide incision-less removal of fibroids and polyps within the uterus. The Skeletal Health segment products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and Fluoroscan mini C-arm imaging products. The company was founded by S. David Ellenbogen and Jay A. Stein in October, 1985 and is headquartered in Bedford, MA.

Description

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The Diagnostics segment provides Aptima family of assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assays, Procleix family of assays for blood screening, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test. The Breast Health segment offers breast imaging and related products and accessories, including digital and film-based mammography systems; computer-aided detection (CAD) for mammography; invasive breast biopsy devices; breast biopsy site markers; and breast biopsy guidance systems. This segment also provides Dimensions platform, a mammography gantry for 2D and tomosynthesis image acquisition and display; C-View that provides a 2D image; Selenia digital mammography platform; and SecurView Workstation. The GYN Surgical segment offers NovaSure system to treat women suffering from abnormal uterine bleeding; and MyoSure system for the hysteroscopic removal of fibroids. The Skeletal Health segment provides discovery and horizon X-ray bone densitometers that assess the bone density of fracture sites; and mini C-arm imaging systems to perform minimally invasive surgical procedures on a patient's extremities, such as the hand, wrist, knee, foot, and ankle. The company sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. Hologic, Inc. was founded in 1985 and is headquartered in Marlborough, Massachusetts.